Kiniksa Pharmaceuticals International, plc cash flow statement

In fiscal 2025, Kiniksa Pharmaceuticals International, plc's operations generated $138m of cash; it spent $1.6m on capital projects, leaving free cash flow of $136m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kiniksa Pharmaceuticals International, plc: cash flow statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMSept 2026
Cash from operations	−126	6	13	26	138	199
Depreciation and amortisation	2	2	2	2	2	1
Stock-based pay	25	25	27	31	37	45
Capital spending	0	0	0	0	2	2
Free cash flow	−127	6	13	25	136	197
Free cash flow after stock pay	−152	−19	−14	−5	99	152

US$ millions unless shown otherwise. Fiscal quarters.

Kiniksa Pharmaceuticals International, plc: cash flow statement, quarterly
Quarter	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026	2026 Q3Sept 2026
Cash from operations	19	22	28	34	54	50	47	48
Depreciation and amortisation	0	0	0	0	0	0	0	0
Stock-based pay	8	8	9	10	10	10	12	13
Capital spending	0	0	0	1	1	0	1	0
Free cash flow	19	22	28	33	53	50	47	47
Free cash flow after stock pay	10	14	19	23	43	40	35	34

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BBIO vs KNSA BCRX vs KNSA IONS vs KNSA KNSA vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kiniksa Pharmaceuticals International, plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kiniksa Pharmaceuticals International, plc.